Insider buying last 90 days
No open-market insider purchases were filed for GRFS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Grifols moved this week on third-quarter results and dividend news. The company reported Q3 2026 results alongside an interim dividend of €0.15 per share, which Gekko's summary describes as stabilizing investor sentiment and lifting the share price. Separately, Wall Street Zen and JPMorgan Chase & Co. lowered their rating and price targets on the stock, even as another commentary pointed to revenue above €2 billion for the quarter, EBITDA up 10%, net profit up 28%, and leverage below 4x, with management reiterating full-year targets despite continued weakness in China's albumin market.
Shares closed at $8.69, up 3.1% on the day, sitting between the 50-day average of $7.67 and the 200-day average of $7.99. The GekkoIndex reads 41.2, placing the stock in the Distribution zone. Price remains 29.9% below Gekko Fair Value of $12.39.
Over the next 20 trading days, the next earnings date falls on 4 March 2027, well outside this window. No insider, Congress or unusual options activity appears in their respective 90-day and 30-day windows, and there are no billionaire or trailblazer holders recorded. Seasonality over this stretch has averaged -0.7% across 5 years, rising in 3 of them. The sole covered analyst holds a hold rating, with a consensus target of $10.37 implying 19.3% upside. The gap to Gekko Fair Value bears watching given the Distribution reading.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Grifols scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Averages disagree
Close $8.69 sits between the 50-day ($7.75) and 200-day ($7.98) averages, or the averages disagree.
See the chart45.9, Neutral
Reading 45.9 is in the Neutral zone.
See the GekkoIndex27.1% below
Price is 27.1% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 109 days
Next report Mar 4, 2027, 109 days away — outside a typical 20-trading-day hold.
See earnings−2.4% on average
From this point in the calendar, the next 20 trading days averaged −2.4% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Grifols closed at $8.69 on Nov 13, 2026, 0.0% over the past year, inside a 52-week range of $6.96 to $9.77.
Use the left and right arrow keys to read daily values.
Put GRFS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Grifols works mainly with human plasma, turning it into medicines used to manage serious and long-term illnesses. Among its most recognized products are immunoglobulins, alpha-1 antitrypsin, albumin and clotting factors, which help address conditions like hemophilia and problems with the immune system. The company also supplies hospitals with pharmaceutical items that are not biological in nature, along with medical devices, nutrition products for clinical settings and intravenous solutions.
Its business spans several distinct areas. One focuses on researching and marketing plasma-based treatments, another handles hospital-related supplies, and a further division builds diagnostic tools used at every stage of patient care, from early screening through to tracking treatment progress. A separate arm distributes biological materials needed for scientific research, clinical testing and the production of drugs and diagnostic goods. Buyers of these products include hospitals, blood banks, wholesalers, distributors, purchasing groups and both public and private health systems, and the company also works with Mondragon under a shared technology arrangement.
Grifols traces its origins to 1940 and runs its operations from Barcelona, Spain. Its stock can be found under the ticker GRFS.
Grifols’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.9, in the Neutral zone, up 2.4 points over five sessions.
Up 2.4 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 24 | +4.5% | +7.9% | ||
| Accumulation | 240 | +0.4% | +2.8% | ||
| Neutral (current zone) | 337 | +0.2% | +0.1% | ||
| Distribution | 54 | −0.5% | −4.3% | ||
| Selling | 0 | Not available | |||
Average GRFS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Grifols trades 27.1% below Gekko Fair Value of $11.92, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Grifols shares are worth, recalculated every trading day.
$11.92
Gekko Fair Value, Nov 14, 2026
27.1% Undervalued
At the end of Aug 2026 the price was 45.5% below the estimate.
No open-market insider purchases were filed for Grifols, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for GRFS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in GRFS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold GRFS.
Grifols reports on Mar 4, 2027 (109 days away), and beat the EPS estimate in 1 of its last 8 reports.
Mar 4, 2027
109 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 7, 2026 | $0.13 est $0.15 | $2.00B est $2.03B | −3.7% |
| Feb 26, 2026 | $0.29 est $0.29 | $2.34B est $2.34B | −1.6% |
| Nov 4, 2025 | $0.21 est $0.24 | $2.14B est $2.15B | −8.5% |
| Jul 28, 2025 | $0.22 est $0.28 | $2.17B est $2.20B | +4.0% |
| May 12, 2025 | $0.09 est $0.16 | $1.99B est $1.96B | +10.7% |
| Mar 6, 2025 | $0.11 est $0.23 | — | −3.2% |
| Nov 7, 2024 | $0.17 est $0.24 | — | +4.9% |
| Jul 30, 2024 | $0.15 est $0.23 | — | −3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Grifols is $10.37, +19.3% from the last close, from 1 firm rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 1 firm.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 26 | J.P. Morgan | $9 | +3.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Grifols averaged −2.4% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.4% | 1 of 5 |
| Next 10 trading days | −4.2% | 2 of 5 |
| Next 15 trading days | −4.3% | 2 of 5 |
| Next 20 trading days | −2.4% | 2 of 5 |
| Next 30 trading days | −0.6% | 2 of 5 |
For scale, GRFS’s typical 20-trading-day move in either direction is about 8.7%.
Grifols’s market cap is $7.35B, with a P/E ratio of 10.5 and revenue of $7.60B over the last twelve months.
Coverage of Grifols this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
Grifols’s market cap is $7.35B at the Nov 13, 2026 close of $8.69, with 258.2M shares outstanding. The shares trade on a P/E ratio of 10.5.
The consensus analyst 12-month price target for Grifols is $10.37, +19.3% from the last close. Of the 1 firm that rated the stock in the last 90 days, 0 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Grifols is undervalued: the Nov 13, 2026 close of $8.69 is 27.1% below Gekko Fair Value of $11.92. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Grifols is expected to report on Mar 4, 2027 (109 days away). Analysts expect earnings of $0.33 per share on revenue of $2.31B. Grifols beat the earnings estimate in 1 of its last 8 reports, moving 5% on average across the report.
Grifols’s 52-week high is $9.77 and its 52-week low is $6.96; it closed at $8.69 on Nov 13, 2026, 0.0% over the past year. Over the last five years the shares peaked at $13.34 on May 24, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.